

Caprihans India Limited

Head Office

601, ICC Trade Towers,
Senapati Bapat Road,
Pune, Maharashtra 411016 India
Tel +91 20 6749 0100

Email: -cil@caprihansindia.com
Website: www.caprihansindia.com

Bilcare
Research

August 12, 2024

The Secretary
BSE Ltd
Dept. of Corporate Services,
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Outcome of Board Meeting held on August 12, 2024

Ref: Scrip Code No – 509486

We refer to the above subject and enclose herewith the following:

1. Unaudited Financial Results for the quarter ended June 30, 2024 duly approved by Board of Directors at its Meeting held on August 12, 2024.
2. Limited review certificate dated August 12, 2024, issued by M/s Batliboi & Purohit, Chartered Accountants, Mumbai, Statutory Auditors of the Company, regarding Unaudited Financial Results for the quarter ended June 30, 2024.

The meeting of Board of Directors commenced at 3.00 p.m. and concluded at 5.45 p.m.

Thanking you

Yours faithfully

For Caprihans India Limited


Pritam Paul
CFO & Company Secretary



Encl: as above

Caprihans India Limited

Registered Office: 1028 Shiroli, Rajgurunagar, Pune 410505 Tel : +91 21 35647300

Email : cil@caprihansindia.com Website : www.caprihansindia.com

CIN : L29150MH1946PLC004877

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs. In Crores)

Sr No	Particulars	Quarter ended			Year Ended
		June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
		(unaudited)	(audited)	(unaudited)	(audited)
1	Income				
	(a) Revenue from operations	178.25	188.05	168.82	694.53
	(b) Other Operating Income	4.10	2.93	2.27	9.66
	Total Revenue from Operations	182.35	190.98	171.09	704.19
	(c) Other Income	3.82	5.06	4.86	17.93
	Total Income (1)	186.17	196.04	175.95	722.12
2	Expenses				
	a) Cost of Materials consumed	125.37	141.91	114.48	484.46
	b) Purchase of Traded Goods	0.01	0.07	0.11	1.76
	c) Changes in Inventories of finished goods, work-in-progress	(4.96)	(8.78)	3.00	(7.88)
	d) Employee Benefits Expense	16.12	17.04	17.47	64.93
	e) Finance Costs	20.97	21.81	19.51	82.68
	f) Depreciation and Amortisation expense	10.80	12.81	10.07	42.98
	g) Other expenses	30.38	45.67	22.37	116.93
	Total Expenses (2)	198.69	230.53	187.01	785.86
3	Profit/(Loss) before exceptional items and tax (1-2)	(12.52)	(34.49)	(11.06)	(63.74)
4	Exceptional Item net (Expense)/Income	-	-	-	(1.60)
5	Profit/(Loss) before Tax after exceptional item (3+4)	(12.52)	(34.49)	(11.06)	(65.34)
6	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Adjustment of tax relating to earlier years	-	-	(4.48)	(4.48)
	c) Deferred Tax	5.09	(16.58)	4.09	(9.24)
	Total Tax Expense (6)	5.09	(16.58)	(0.39)	(13.72)
7	Profit/(Loss) for the period (5-6)	(17.61)	(17.91)	(10.67)	(51.62)
8	Other Comprehensive Income				
	a. Items that will not be reclassified to Profit or Loss				
	(i) Remeasurement gain/(losses) on defined benefit plans	-	1.36	(0.20)	0.77
	(ii) Tax impact	-	(0.32)	0.05	(0.18)
8	Total Other Comprehensive Income	-	1.04	(0.15)	0.59
9	Total Comprehensive Income for the period (7+8)	(17.61)	(16.87)	(10.82)	(51.03)
10	Paid-up equity share capital (face value of Rs 10 per share)	13.13	13.13	13.13	13.13
11	Reserves excluding revaluation reserves as per the Balance sheet of the respective accounting year	-	-	-	(144.66)
12	Earnings per share (not annualised)				
	Basic and Diluted (Amount in Rs.)	(13.41)	(13.64)	(8.13)	(39.31)



Caprihans India Limited

Registered Office: 1028 Shiroli, Rajgurunagar, Pune 410505 Tel : +91 21 35647300

Email : cil@caprihansindia.com Website : www.caprihansindia.com

CIN : L29150MH1946PLC004877

Notes:

- 1 The Company is engaged mainly in processing of plastic polymers and Pharma Packaging Solutions and its products are covered under a single reportable segment.
- 2 The above results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 Exceptional Items represents loss on sale of office premises, for the year ended March 31, 2024.
- 4 In respect of the arrangement with Bilcare Limited for the repayment of principal and interest on the public fixed deposit liability taken over by the Company as per the Business Transfer Agreement, the outstanding as at June 30, 2024 is Rs 68.91 crores(including interest). The statutory compliances related to Public fixed deposit is the responsibility of Bilcare Limited. Out of the total loan amount of Rs 57 crores disbursed by the bank to repay the said public fixed deposits, Rs 13.97 crores has been earmarked in term deposit with the lead bank and the amount of Rs 2.02 crores is in escrow account with the lead Bank.
- 5 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2024. The results have been reviewed by the Statutory Auditors of the Company
- 6 The results for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the un-audited year to date figures up to the third quarter of the financial year.
- 7 Previous periods' figures have been re-grouped / re-classified wherever necessary.

For Caprihans India Limited

Ankita J.

Ankita J. Kariya
Managing Director



Pune: August 12, 2024

BATLIBOI & PUROHIT


Chartered Accountants

Independent Auditor's Limited Review Report on Unaudited Quarterly Financial Results

To the Board of Directors of Caprihans India Limited

1. We have reviewed the accompanying statement of unaudited financial results of Caprihans India Limited ('the Company') for the quarter ended June 30, 2024 ('the Statement') being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standard, prescribed under Section 133 of the Act, and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to note 4 of the Statement pertaining to the arrangement and agreement with Bilcare Limited ("the Bilcare") in respect of repayment of principal and interest on the Public Fixed Deposit liability taken over by the Company, having carrying amount of Rs 109.60 crores as at March 27, 2023 as per the Slump Sale Agreement, which had matured but remained unpaid by the Pharma Packaging Innovation (PPI) division of Bilcare. As per the agreement the statutory compliances related to Public Fixed Deposit under the Companies Act, 2013 is the responsibility of Bilcare. As on June 30, 2024 the total outstanding amount of the aforesaid Public Fixed Deposit liability is Rs 68.91 crores.
Our conclusion is not modified in respect of the above matter.

For Batliboi & Purohit
Chartered Accountants
Firm Registration No. 101048W


Kaushal Mehta
Partner

Membership no 111749
ICAI UDIN : 24111749BKAFJC8033



Place : Mumbai
Date : August 12, 2024